Baillie Gifford & CO Genmab A/S Transaction History
Baillie Gifford & CO
- $128 Billion
- Q3 2025
Shares
4 transactions
Others Institutions Holding GMAB
# of Institutions
252Shares Held
65.2MCall Options Held
32.5KPut Options Held
55K-
Alliancebernstein L.P. New York, NY10.7MShares$305 Million0.08% of portfolio
-
Orbis Allan Gray LTD Hamilton, D07.92MShares$227 Million1.07% of portfolio
-
Black Rock Inc. New York, NY5.08MShares$145 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.57MShares$102 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.45MShares$98.8 Million0.05% of portfolio
About GENMAB A/S
- Ticker GMAB
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 658,292,992
- Market Cap $18.8B
- Description
- Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...